136 related articles for article (PubMed ID: 105806)
1. Phase I--II study of hexamethylmelamine plus dibromodulcitol in refractory carcinoma of the breast.
Van Amburg AL; Presant CA; Vélez-García E; Klahr C
Cancer Treat Rep; 1979 Jan; 63(1):141-2. PubMed ID: 105806
[No Abstract] [Full Text] [Related]
2. A phase III study in lung carcinoma comparing hexamethyl-melamine (NSC 13875) to dibromodulcitol (NSC 104800) 1,2.
Wilson WL; Ryzin JV; Weiss AJ; Frelick RW; Moss SE
Oncology; 1975; 31(5-6):293-309. PubMed ID: 174041
[TBL] [Abstract][Full Text] [Related]
3. Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy.
Denefrio JM; Vogel CL
Cancer Treat Rep; 1978 Jan; 62(1):173-5. PubMed ID: 414835
[No Abstract] [Full Text] [Related]
4. Preliminary report on the use of CCNU (NSC-79037), adriamycin (NSC-123127), and hexamethylmelamine (NSC-13875) in carcinoma of the lung.
Wilson WL; Andrews NC; Frelick RW; Nealon TF; Bick RL; Adams T
Cancer Treat Rep; 1976 Mar; 60(3):269-71. PubMed ID: 816467
[No Abstract] [Full Text] [Related]
5. Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group study.
Fabian CJ; Rasmussen S; Stephens R; Haut A; Smith F; Balcerzak S; Tranum B
Cancer Treat Rep; 1979 Aug; 63(8):1359-61. PubMed ID: 113095
[TBL] [Abstract][Full Text] [Related]
6. Hexamethylmelamine, vincristine, and methotrexate chemotherapy in advanced neoplasms.
Longacre D; Donavan M; Paladine W; Cunningham T; Sponzo R
Cancer Treat Rep; 1977 Aug; 61(5):919-22. PubMed ID: 408004
[No Abstract] [Full Text] [Related]
7. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
[No Abstract] [Full Text] [Related]
8. Phase II study of hexamethylmelamine for disseminated prostatic carcinoma.
Drelichman A; Brownlee R; Al-Sarraf M
Cancer Clin Trials; 1981; 4(3):309-12. PubMed ID: 6793256
[TBL] [Abstract][Full Text] [Related]
9. cis-Dichlorodiammineplatinum(II) and hexamethylmelamine in the treatment of non-oat cell lung cancer: a pilot study of the Southeastern Cancer Study Group.
Krauss S; Tornyos K; DeSimone P; Lowenbraun S; McKeown J; Solomon A; Sonoda T
Cancer Treat Rep; 1979 Mar; 63(3):391-3. PubMed ID: 106964
[TBL] [Abstract][Full Text] [Related]
10. [Effectiveness of ftorafur and hexamethylmelamine in advanced breast cancer].
Lichinitser MR; Perevodchikova NI; Garin AM; Asserkritova IV; Vaarik GKh
Vopr Onkol; 1978; 24(8):60-5. PubMed ID: 99870
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26.
Gad-el-Mawla NM; Muggia FM; Hamza MR; El-Morsi B; Sherif M; Mansour MA; Khafagy M; El-Sebai IT
Cancer Treat Rep; 1978 Jul; 62(7):993-6. PubMed ID: 99234
[No Abstract] [Full Text] [Related]
12. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
Kardinal CG; Luce JK
Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of hexamethylmelamine, cis-diamminedichloroplatinum, and mitomycin-C in advanced breast cancer. A pilot study of the Southeastern Cancer Study Group.
Lawson D; Moore M; Smalley R
Cancer Clin Trials; 1980; 3(4):293-6. PubMed ID: 6775826
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of adriamycin and dibromodulcitol in metastatic breast carcinoma.
Tormey DC; Simon R; Falkson G; Bull J; Band P; Perlin E; Blom J
Cancer Res; 1977 Feb; 37(2):529-34. PubMed ID: 832277
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of hexamethylmelamine versus pentamethylmelamine in carcinoma of the bilharzial bladder.
Gad-el-Mawla N; Ziegler JL; Hamza R; Elserafi M; Khaled H
Cancer Treat Rep; 1984 May; 68(5):793-4. PubMed ID: 6426792
[No Abstract] [Full Text] [Related]
16. Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP).
DiStefano A; Yap HY; Blumenschein GR
Cancer Treat Rep; 1981; 65(1-2):33-8. PubMed ID: 7013977
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer.
Creech RH; Catalano RB; Dierks KM; Shah MK
Cancer Treat Rep; 1984 Dec; 68(12):1499-501. PubMed ID: 6548936
[TBL] [Abstract][Full Text] [Related]
18. Contribution of prednisone to the effectiveness of hexamethylmelamine in multiple myeloma.
Oken MM; Lenhard RE; Tsiatis AA; Glick JH; Silverstein MN
Cancer Treat Rep; 1987 Sep; 71(9):807-11. PubMed ID: 3113729
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma.
Legha SS; Buzdar AU; Hortobagyi GN; DiStefano A; Wiseman CL; Yap HY; Blumenschein GR; Bodey GP
Cancer Treat Rep; 1979; 63(11-12):2053-6. PubMed ID: 118805
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of hexamethylmelamine in refractory Hodgkin's disease, other lymphomas, and chronic lymphocytic leukemia.
Omura GA; Broun GO; Papps J; Birch R
Cancer Treat Rep; 1981; 65(11-12):1027-9. PubMed ID: 6794907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]